22
May 2026
New discovery maps how mutant colorectal tumors adapt to KRAS inhibitors
A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer.